X0609 4 2026-08-07 0 0001638097 Entera Bio Ltd. ENTX 0001424383 Germano Geno J true KIRYAT HADASSAH, MINRAV BUILDING 5TH FLOOR JERUSALEM L3 9112002 ISRAEL 1 0 0 0 0 Ordinary Shares, par value NIS 0.0000769 per share 2026-08-07 4 A 0 25014 0 A 65014 D Stock Option (right to buy) 1.37 2026-08-07 4 A 0 50000 0 A 2036-05-07 Ordinary Shares, par value NIS 0.0000769 per share 50000 50000 D Stock Option (right to buy) 1.37 2026-08-07 4 A 0 43014 0 A 2036-05-07 Ordinary Shares, par value NIS 0.0000769 per share 43014 43014 D The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026. Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 4, 2026, with one-third of the options vesting on February 4, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")). Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 4, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan). /s/ Dana Yaacov-Garbeli, Attorney-in-Fact 2026-08-07